167 related articles for article (PubMed ID: 35655123)
1. Phase 1 and preclinical profiling of ESM-HDAC391, a myeloid-targeted histone deacetylase inhibitor, shows enhanced pharmacology and monocytopaenia.
Furze RC; Molnar J; Parr NJ; Ahmad F; Henry Y; Howe D; Singh R; Toal M; Bassil AK; Bernard SG; Davis RP; Gibson A; Maller NC; Sharp C; Tough DF; Prinjha RK; Lewis HD
Br J Clin Pharmacol; 2022 Dec; 88(12):5238-5256. PubMed ID: 35655123
[TBL] [Abstract][Full Text] [Related]
2. Carboxylesterase-1 Assisted Targeting of HDAC Inhibitors to Mononuclear Myeloid Cells in Inflammatory Bowel Disease.
Elfiky AMI; Ghiboub M; Li Yim AYF; Hageman IL; Verhoeff J; de Krijger M; van Hamersveld PHP; Welting O; Admiraal I; Rahman S; Garcia-Vallejo JJ; Wildenberg ME; Tomlinson L; Gregory R; Rioja I; Prinjha RK; Furze RC; Lewis HD; Mander PK; Heinsbroek SEM; Bell MJ; de Jonge WJ
J Crohns Colitis; 2022 May; 16(4):668-681. PubMed ID: 34633041
[TBL] [Abstract][Full Text] [Related]
3. Targeting Histone Deacetylases in Myeloid Cells Inhibits Their Maturation and Inflammatory Function With Limited Effects on Atherosclerosis.
Luque-Martin R; Van den Bossche J; Furze RC; Neele AE; van der Velden S; Gijbels MJJ; van Roomen CPPA; Bernard SG; de Jonge WJ; Rioja I; Prinjha RK; Lewis HD; Mander PK; de Winther MPJ
Front Pharmacol; 2019; 10():1242. PubMed ID: 31736752
[TBL] [Abstract][Full Text] [Related]
4. Drug targeting to monocytes and macrophages using esterase-sensitive chemical motifs.
Needham LA; Davidson AH; Bawden LJ; Belfield A; Bone EA; Brotherton DH; Bryant S; Charlton MH; Clark VL; Davies SJ; Donald A; Day FA; Krige D; Legris V; McDermott J; McGovern Y; Owen J; Patel SR; Pintat S; Testar RJ; Wells GM; Moffat D; Drummond AH
J Pharmacol Exp Ther; 2011 Oct; 339(1):132-42. PubMed ID: 21778281
[TBL] [Abstract][Full Text] [Related]
5. A phase I first-in-human study with tefinostat - a monocyte/macrophage targeted histone deacetylase inhibitor - in patients with advanced haematological malignancies.
Ossenkoppele GJ; Lowenberg B; Zachee P; Vey N; Breems D; Van de Loosdrecht AA; Davidson AH; Wells G; Needham L; Bawden L; Toal M; Hooftman L; Debnam PM
Br J Haematol; 2013 Jul; 162(2):191-201. PubMed ID: 23647373
[TBL] [Abstract][Full Text] [Related]
6. A BET Protein Inhibitor Targeting Mononuclear Myeloid Cells Affects Specific Inflammatory Mediators and Pathways in Crohn's Disease.
Elfiky AMI; Hageman IL; Becker MAJ; Verhoeff J; Li Yim AYF; Joustra VW; Mulders L; Fung I; Rioja I; Prinjha RK; Smithers NN; Furze RC; Mander PK; Bell MJ; Buskens CJ; D'Haens GR; Wildenberg ME; de Jonge WJ
Cells; 2022 Sep; 11(18):. PubMed ID: 36139421
[TBL] [Abstract][Full Text] [Related]
7. Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat.
Maxwell JW; Falcinelli SD; Nefedov A; Dorfmeier C; Wu G; Dewey M; Webber AL; Archin NM; Margolis DM; Hazuda DJ; Barnard RJO; Howell BJ
J Virol; 2020 Jun; 94(13):. PubMed ID: 32295913
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitors deplete myeloid-derived suppressor cells induced by 4T1 mammary tumors in vivo and in vitro.
Wang HF; Ning F; Liu ZC; Wu L; Li ZQ; Qi YF; Zhang G; Wang HS; Cai SH; Du J
Cancer Immunol Immunother; 2017 Mar; 66(3):355-366. PubMed ID: 27915371
[TBL] [Abstract][Full Text] [Related]
9. Inhibiting histone deacetylase 1 suppresses both inflammation and bone loss in arthritis.
Cantley MD; Fairlie DP; Bartold PM; Marino V; Gupta PK; Haynes DR
Rheumatology (Oxford); 2015 Sep; 54(9):1713-23. PubMed ID: 25832610
[TBL] [Abstract][Full Text] [Related]
10. ARHGEF3 controls HDACi-induced differentiation via RhoA-dependent pathways in acute myeloid leukemias.
D'Amato L; Dell'Aversana C; Conte M; Ciotta A; Scisciola L; Carissimo A; Nebbioso A; Altucci L
Epigenetics; 2015; 10(1):6-18. PubMed ID: 25494542
[TBL] [Abstract][Full Text] [Related]
11. P21-driven multifusion gene system for evaluating the efficacy of histone deacetylase inhibitors by in vivo molecular imaging and for transcription targeting therapy of cancer mediated by histone deacetylase inhibitor.
Hsieh YJ; Hwu L; Chen YC; Ke CC; Chen FD; Wang HE; Lin KP; Yeh HH; Chang CW; Liu RS
J Nucl Med; 2014 Apr; 55(4):678-85. PubMed ID: 24639460
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylases 1 and 2 inhibition suppresses cytokine production and osteoclast bone resorption in vitro.
Algate K; Haynes D; Fitzsimmons T; Romeo O; Wagner F; Holson E; Reid R; Fairlie D; Bartold P; Cantley M
J Cell Biochem; 2020 Jan; 121(1):244-258. PubMed ID: 31222845
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of ERK-EGR1-heparanase axis by HDAC inhibitors provides targets for rational therapeutic intervention in synovial sarcoma.
Lanzi C; Favini E; Dal Bo L; Tortoreto M; Arrighetti N; Zaffaroni N; Cassinelli G
J Exp Clin Cancer Res; 2021 Dec; 40(1):381. PubMed ID: 34857011
[TBL] [Abstract][Full Text] [Related]
14. First-in-human study of the toxicity, pharmacokinetics, and pharmacodynamics of CG200745, a pan-HDAC inhibitor, in patients with refractory solid malignancies.
Kim KP; Park SJ; Kim JE; Hong YS; Lee JL; Bae KS; Cha H; Kwon SK; Ro S; Cho J; Kim TW
Invest New Drugs; 2015 Oct; 33(5):1048-57. PubMed ID: 26076682
[TBL] [Abstract][Full Text] [Related]
15. Preclinical anti-arthritic study and pharmacokinetic properties of a potent histone deacetylase inhibitor MPT0G009.
Hsieh IN; Liou JP; Lee HY; Lai MJ; Li YH; Yang CR
Cell Death Dis; 2014 Apr; 5(4):e1166. PubMed ID: 24722291
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitors SAHA and sodium butyrate block G1-to-S cell cycle progression in neurosphere formation by adult subventricular cells.
Zhou Q; Dalgard CL; Wynder C; Doughty ML
BMC Neurosci; 2011 May; 12():50. PubMed ID: 21615950
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells.
Dejligbjerg M; Grauslund M; Litman T; Collins L; Qian X; Jeffers M; Lichenstein H; Jensen PB; Sehested M
Mol Cancer; 2008 Sep; 7():70. PubMed ID: 18789133
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibition facilitates GM-CSF-mediated expansion of myeloid-derived suppressor cells in vitro and in vivo.
Rosborough BR; Castellaneta A; Natarajan S; Thomson AW; Turnquist HR
J Leukoc Biol; 2012 May; 91(5):701-9. PubMed ID: 22028329
[TBL] [Abstract][Full Text] [Related]
19. The targeted histone deacetylase inhibitor tefinostat (CHR-2845) shows selective in vitro efficacy in monocytoid-lineage leukaemias.
Zabkiewicz J; Gilmour M; Hills R; Vyas P; Bone E; Davidson A; Burnett A; Knapper S
Oncotarget; 2016 Mar; 7(13):16650-62. PubMed ID: 26934551
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of myeloid HDAC2 upregulates glutaredoxin 1 expression, improves protein thiol redox state and protects against high-calorie diet-induced monocyte dysfunction and atherosclerosis.
Wang L; Ahn YJ; Asmis R
Atherosclerosis; 2021 Jul; 328():23-32. PubMed ID: 34077868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
